Press Release

Cyxone presents at Aktiedagen the 27 January 2021

January 20, 2021 09:20 (CET)

CEO Tara Heitner will present the latest updates in Cyxone on 27 January at 20.30 at the online event Aktiedagen. Information about the event together with the agenda is found on the event’s webpage ( Follow the presentation live here (


Tara Heitner, CEO
Tel: +46 70 781 88 08
Adelgatan 21
211 22 Malmö, Sweden

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, For more information, please visit

Open Press release